Apparatus and method for obtaining protein-enriched fractions from breast milk

Information

  • Patent Grant
  • 12152058
  • Patent Number
    12,152,058
  • Date Filed
    Friday, March 10, 2023
    a year ago
  • Date Issued
    Tuesday, November 26, 2024
    26 days ago
  • Inventors
    • Yudina; Zinaida
  • Original Assignees
  • Examiners
    • Kosanovic; Helena
    • Tran; Tiffany T
    Agents
    • Morrison & Foerster LLP
Abstract
A device for obtaining protein-enriched fractions from human or animal milk comprises a delipidating unit for reducing a lipid content in the human or animal milk to obtain delipidated milk and a filtering unit for increasing a protein concentration of the delipidated milk to obtain the protein-enriched fraction, comprising a replaceable filter having a nominal molecular weight limit of 2 kDa or more, in particular of 5 kDa or more.
Description
TECHNICAL FIELD

The present invention relates to a device and a method for obtaining protein-enriched fractions from human or animal milk as well as to a protein-enriched fraction of milk obtained from the method and to a use thereof.


BACKGROUND ART

Breastfeeding with breast milk is commonly regarded as very important for the development of newborns. Breastmilk is uniquely adapted to the needs of human babies, providing them with the nutrients they need to grow and thrive, but at the same time incorporating a multitude of immunological, antibacterial and in general antipatogenic factors and epigenetic effects that the industry needs can not be reproduced. Bioactive proteins can have enzymatic activity, enhance nutrient absorption, stimulate growth, modulate the immune system and assist in the defense against pathogens. Key bioactive proteins in human milk include lysozyme, α-lactalbumin, κ-casein and β-casein, as well as lactoferrin and immunoglobulins, especially sIgA [1] (REF: [1] B. Löhnerdal, P. Erdmann, S. K. Thakkar, J. Sauser, and F. Destaillats, “Longitudinal evolution of true protein, amino acids and bioactive proteins in breast milk: a developmental perspective,” Journal of Nutritional Biochemistry. 2017 and [2] C. R. Martin, P. R. Ling, and G. L. Blackburn, “Review of infant feeding: Key features of breast milk and infant formula,” Nutrients. 2016.)


Breast milk is the only known substance that has nourishing and at the same time immune-modulating functions for the child organism. The composition of breast milk changes over time. And there are suggestions that at the end of first year and after the nourishing function of breastfeeding in newborns decreases at the age of one year and above, and the immune-modulating function increases [REF: B. VAN'T LAND, G. BOEHM, J. GARSSEN: Breast Milk: Components with Immune Modulating Potential and Their Possible Role in Immune Mediated Disease Resistance, in: Dietary Components and Immune Function, 2010; M. T. PERRIN, A. FOGLEMAN, J. C. ALLEN: The nutritive and immunoprotective quality of human milk beyond 1 year postpartum: are lactation-duration-based donor exclusions justified? In Journal of Human Lactation. 2013].


Still, breastfeeding rates are generally too low, especially in developed countries. Due to socio-economic conditions, and especially because of their professional activity, women often do not have enough time to fulfill the ideal breastfeeding criteria (continuous breastfeeding, ie breastmilk with solid food) for up to two years and beyond. In developed countries, only 25% of mothers quit after 10 months or more [REF: C. G. VICTORA ET AL.: Breast feeding in the 21st century: Epidemiology, mechanisms, and lifelong effect, in The Lancet, vol. 387, no. 10017. pp. 475-490].


In order to close the gap between the actual breastfeeding rate and the physiological needs of babies infant formula milk products are available, mainly based on cow's milk. However, these products are inferior to breast milk in their physiological effects. In particular, they absolutely can not fulfill the immunomodulatory functions of breast milk [REF: N. J. ANDREAS, B. KAMPMANN, K. MEHRING LE-DOARE: Human Breast Milk: A review of its composition and bioactivity, in Early Human Development, vol. 91, no. 11. pp. 629-635, 2015; J. PENDERS: Early diet and the infant good microbiome How breastfeeding and solid foods shape the microbiome, in Microbiota in health and disease: from pregnancy to childhood, 2017].


A particular problem is revealed in premature infants. Also, they ideally need breast milk (from their mother or a donor). However, the composition of human milk is not geared to the needs of premature babies. Premature babies need a higher protein content. As a result of protein deficiency, there is a risk that premature babies are disturbed in their growth. To counteract this problem, cow's milk, donkey's milk or soy proteins are added to the donor milk in order to increase their nutritional value (so-called enrichment process). However, enrichment with proteins of non-human origin leads to risks, in particular for gastrointestinal diseases, increased risks of infection increased risk of allergies and increase the risk of NEC—the leading mortality cause of preterm babies [REF: T. T. Colaizy et al.: Impact of Optimized Breast Feeding on the Cost of Necrotizing Enterocolitis in Extremely Low Birthweight Infants, in J. Pediatr., 2016; N. D. Embleton et al.: Effectiveness of Human Milk-Based Fortifiers for Preventing Necrotizing Enterocolitis in Preterm Infants: Case Not Proven, Breastfeed. Med., 2013].


Processes for obtaining protein-enriched fractions from breast milk are known and have been described, inter alia in EP 0 173 999 A2 (Biotest Pharma GmbH). The pH of the milk is reduced and the milk is filtered using a cross-flow filtration unit. Low-molecular weight components are removed from the resulting filtrate by a second cross-flow filtration.


Isolation and/or enrichment of protein-rich fractions from milk is now commonly done by means of laboratory methods by appropriately trained professionals.


SUMMARY OF THE INVENTION

It is the object of the invention to create a device for obtaining protein-enriched fractions from human or animal milk pertaining to the technical field initially mentioned, that simplifies the process, especially for on-site application.


The solution of the invention is specified by the features of claim 1. According to the invention the device comprises

    • a) a delipidating unit for reducing a lipid content in the human or animal milk to obtain delipidated milk; and
    • b) a filtering unit for increasing a protein concentration of the delipidated milk to obtain the protein-enriched fraction, comprising a replaceable filter having a nominal molecular weight limit (NMWL) of 2 kDa or more, in particular of 5 kDa or more.


In the filtering unit, an ultrafiltration step takes place. In particular, the corresponding filter has a membrane pore size which is at least two times less than the weight of the target molecules in the permeate. The pore size can be varied so that the filtrate has the desired proteins. Usually, the NMWL it should not exceed 10 kDa.


Preferably, the delipidating unit and the filtering unit are integrated as components of the device. However, these units can also be configured as separate modules or modules that can be combined to form a structural unit. The device is a functional unit that allows the recovery of protein-enriched fractions from the human or animal breast milk outside the laboratory. The device may be designed in such a way that its use does not require any professional laboratory knowledge, but may also be used by laymen (especially mothers and nurses).


According to the invention, a method for obtaining protein-enriched fractions from human or animal milk, comprises the steps of:

    • a) reducing a lipid content in the human or animal milk to obtain delipidated milk; and
    • b) increasing a protein concentration of the delipidated milk to obtain the protein-enriched fraction by filtering the delipidated milk using a filter having a nominal molecular weight limit of 2 kDa or more, in particular of 5 kDa or more.


In particular, the pH of the milk is not modified, but the product is obtained substantially be reducing the lipid content and subsequent filtering.


Reducing the lipid content avoids fouling of the nanofilter for the increase of protein concentration.


The present invention provides an easy-to-use device or an easily performed method which allows the isolation of protein-enriched fractions of breast milk even by persons without laboratory technical knowledge, in particular also by mothers and nurses. In particular, the present invention gives mothers the opportunity to stock up on their newborn important fractions of breast milk to continue to provide for the infant even after breastfeeding has stopped. However, the present invention also makes it possible, with a view to the optimal nutrition of preterm infants, to condition breast milk in its ingredients (in particular with regard to protein content). Also conceivable are other applications of the present invention, in particular in the field of recovery of breast milk or of fractions thereof by nurses.


The suggested device allows for substantially reducing the final cost of human milk origin fortifiers (HMOF) compared with current industrial products.


It makes them more available in developed countries and especially in developing ones, providing better outcome for preterm infants. HMOF wide administration would reduce also the total duration of hospitalization of the infants, meaning less spending for hospitals.


If hospitals prepare the protein fortifier from the milk, collected locally, it reduces also the cost of the donor milk itself and thus can decrease further the price of HMOF prepared using the inventive device and method on site. Furthermore, the impact on the environment may be reduced because the product does not have to be shipped, it is prepared on site for local consumption.


Depending on the indication, the filtrate of the filtered permeate is suitable for direct administration to the premature or newborn or for preservation in stock. The present invention may also be applied to the rearing of animals, including within the framework of zoological breeding programs.


Due to the simple device and method, the risk of losing proteins is substantially reduced compared to long elaborative protocols with multiple steps. Accordingly, the protein yield after enrichment may be increased.


Preferably, the delipidating unit comprises a replaceable filter. In the corresponding delipidating unit, the filtrated, delipidated milk (filtrate) with the immunoglobulins, alpha-lactalbumin, serum albumin, lactoferrin and the other components (lactose, minerals, micronutrients etc.) is obtained as permeate.


In today's large scale processes, delipidation is usually based on centrifugation because it was assumed that filters would be immediately blocked by the lipids. Surprisingly, it has been found that the composition of human milk lipid micelles allows to have an efficient filtering process—compared to e. g. cow micelles. It is not even mandatory to employ a cross-flow filtering process, but dead-end filtration is also applicable. This simplifies the process and the buildup of a corresponding device.


In a preferred embodiment, the filter of the delipidating device is a glass microfiber filter. It has been found that the micelles, in particular of human milk, stay inside of a multilayer glass microfiber filter.


The filter material may be different, but should be particularly suitable for labile proteins to achieve minimal absorption and protein loss and same time allow to not penetrate the lipid fraction inside the filtrate.


Preferably, the filter of the delipidating device has a pore size of less than 0.5 μm, preferably of less than 0.35 μm. Correspondingly, the lipid content is reduced by microfiltration, employing a filter having a pore size of less than 0.5 μm, preferably of less than 0.35 μm.


Instead of or in addition to a filter the delipidating device may comprise further components, in particular for centrifugation.


Advantageously, the device further comprises a pasteurizing unit for pasteurizing the delipidated milk. In an alternative embodiment, the pasteurizing unit may be arranged to pasteurize the human or animal milk prior to reducing the lipid content.


Preferably, the device further comprises a suction system and/or a pump system cooperating with the delipidating unit and/or the filtering unit to increase filtering efficiency and throughput. In order to provide the driving force for the filtering of the liquid in the first and/or in the second processing step, centrifugation may be employed.


In a preferred embodiment, the delipidating unit and the filtering unit are arranged in a closed system 61 where the delipidated milk is transferred from the delipidating unit to the filtering unit.


A reservoir may be provided in fluid connection with an output of the delipidating unit and with an input of the filtering unit. In this case, a volume of the reservoir is preferably 5 l or less, in particular 2.5 l or less.


In particular, a total volume of the protein-enriched fraction obtained from an initial volume of the human or animal milk is less than a fifth of the initial volume.


Both the delipidation step as well as the concentration step may be run under controlled temperature, e. g. in a controlled temperature environment. Different temperature regimes are possible. In a first regime, both steps are run at a temperature of 0-10° C. to avoid protein degradation and meet biosafety standards.


In a second regime, the temperature is selectively increased for certain substeps, in particular for the concentration step. Doing so increases the filtration process. After filtration, the products may be rapidly cooled.


Other advantageous embodiments and combinations of features come out from the detailed description below and the entirety of the claims.





BRIEF DESCRIPTION OF THE DRAWINGS

The drawings used to explain the embodiments show:



FIG. 1A schematic illustration of an embodiment of the inventive method; and



FIG. 2 a schematic view of an embodiment of the inventive device.





In the figures, the same components are given the same reference symbols.


PREFERRED EMBODIMENTS

The FIG. 1 is a schematic illustration of an embodiment of the inventive method.


The starting product is human breast milk 1. It flows through a first filter 2 having a pore size of 0.2 μm (microfiltration step 10). The filter 2 is a 3-layer glass microfiber filter (GMF), available e. g. from GE Whatman. The filter 2 separates lipids from the rest of the human milk. Due to the small pore size, milk is also partially sterilized as most of the bacteria have a size of 0.5 μm or more. Nevertheless, it is advisable to pasteurize the starting product (or the intermediate product) due to bacteria with irregular shape, spores, etc.


Lipids precipitate on the first filter 2, the intermediate product (permeate) 3 is further treated by application of a second filter 4, having a nominal molecular weight limit of 10 kDa (nanofiltration step 20). Thereby, the concentration of proteins in the intermediate product 3 is increased. The result is a protein enriched fraction 5. Experiments have shown that the protein fraction does not precipitate and remains soluble.


The process is supported by a vacuum applied (as shown in more detail below, in connection with FIG. 2), as indicated by arrow 6. It can be further supported by air pressure. Instead, the driving force for squeezing the liquid through the first filter 2 and/or the second filter 4, centrifugation may be employed.


Both filters 2, 4 are single-usage. They are changed after each batch to avoid bacterial contamination.


The process is applied to batches of milk having a volume of 1.5 l (or less). The desired concentration factor is 10, i. e. the total volume of the protein-enriched fraction obtained from an initial volume of the human or animal milk is about a tenth of the initial volume. This yields a protein-enriched fraction with a protein amount of about 10 g/l.


Laboratory experiments have shown that the delipidation does not cause any significant loss of the total protein content since the filter has a very low unspecific binding capacity, i.e. proteins do not stick to the surface but freely pass the membrane.


The FIG. 2 is a schematic view of an embodiment of the inventive device. The device comprises a first reservoir 51 with a volume of 1.5 l. It may be provided in the form of a bag. The reservoir is connected to the aforementioned replaceable first filter 2, where a valve 52 is arranged in the flow line between the first reservoir 51 and the first filter 2.


The output of the filter 2 is connected to a lid 53 of a second reservoir 54. A vacuum source 55 is also connected to the lid 53 in order to support the flow of the milk through the first filter 2, passing a valve 56. The second reservoir 54 has a volume of 0.5 l. It is connected to a third reservoir 57 with a volume of 0.5 l, the aforementioend second filter being arranged in the passage 58 between the second reservoir 54 and the third reservoir 57. A further connection connects the vacuum source 55 to the passage 58, passing another valve 59. This supports the extraction of the filtrate collected in the third reservoir 57 from the intermediate product stored in the second reservoir 54.


The invention is not limited to the embodiments described above. In particular, the inventive device may be supplemented with further elements to simplify the operation, in particular with respect to the supply and removal of educts and products. The vacuum system may be supplemented or replaced by an air pressure system and/or a pump system, e.g., based on a peristaltic pump. A stirring device 60, e.g., a magnetic stirrer, may be used to prevent accumulation of proteins on the surface of the membrane of the second filter.


Details of the components, such as filter materials and/or pore sizes, may be adapted.

Claims
  • 1. A vertically integrated device for on-site obtaining protein-enriched fractions from human or animal breast milk, comprising: a first reservoir having a volume of 1.5 L or less;a delipidating unit for reducing a lipid content in the human or animal breast milk to obtain delipidated milk, wherein the delipidating unit comprises a single-usage first filter, wherein the first reservoir is connected to the single-usage first filter, wherein a valve is arranged in a flow line between the first reservoir and the single-usage first filter;a second reservoir having a volume of 0.5 L, configured to receive an output of the single-usage first filter;an air pressure system, connected to the second reservoir in order to support a flow of the human or animal breast milk through the first filter passing a second valve;a third reservoir having a volume of 0.5 L, connected to the second reservoir;a filtering unit for increasing a protein concentration of the delipidated milk to obtain the protein-enriched fraction, comprising a single-usage second filter having a membrane and having a nominal molecular weight limit of 2 kDa or more, wherein the single-usage second filter is arranged in a passage between the second reservoir and the third reservoir, and wherein a further connection connects the air pressure system to the passage passing a third valve to support the extraction of filtrate collected in the third reservoir from an intermediate product stored in the second reservoir; anda stirring device configured to prevent accumulation of proteins on a surface of the membrane of the single-usage second filter;wherein (i) the delipidating unit and the filtering unit are vertically integrated; and(ii) the device is configured for on-site application.
  • 2. The device of claim 1, wherein the single-usage first filter of the delipidating unit is a glass microfiber filter.
  • 3. The device of claim 1, wherein the single-usage first filter of the delipidating unit has a pore size of less than 0.5 μm.
  • 4. The device of claim 3, wherein the single-usage first filter of the delipidating unit has a pore size of less than 0.35 μm.
  • 5. The device of claim 1, wherein the delipidating unit and the filtering unit are arranged in a closed system wherein the delipidated milk is transferred from the delipidating unit to the filtering unit.
  • 6. The device of claim 1, wherein the single-usage second filter of the filtering unit has a nominal molecular weight limit of 5 kDa or more.
  • 7. A device for obtaining protein-enriched fractions from human or animal breast milk, comprising: a first reservoir having a volume of 1.5 L or less;a delipidating unit comprising a single-usage first filter, wherein the first reservoir is connected to the single-usage first filter, wherein a first valve is arranged in a flow line between the first reservoir and the single-usage first filter;a second reservoir having a volume of 0.5 L and comprising a lid configured to receive the output of the first filter, wherein the second reservoir further comprises a stirring device;a vacuum source connected through a second valve to the lid of the second reservoir; anda filtering unit comprising a single-usage second filter and a third reservoir, wherein (i) the single-usage second filter is arranged in a passage between the second reservoir and the third reservoir,(ii) the vacuum source is connected through a third valve to the passage; and(iii) the third reservoir has a volume of 0.5 L;wherein the delipidating unit, the second reservoir, the third reservoir, and the filtering unit are vertically integrated in a closed system; andwherein the device is configured for on-site application.
  • 8. The device of claim 7, wherein the single-usage first filter of the delipidating unit is a glass microfiber filter.
  • 9. The device of claim 7, wherein the single-usage first filter of the delipidating unit has a pore size of less than 0.5 μm.
  • 10. The device of claim 9, wherein the single-usage first filter of the delipidating unit has a pore size of less than 0.35 μm.
  • 11. The device of claim 7, wherein the single-usage second filter of the filtering unit has a nominal molecular weight limit of 5 kDa or more.
CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation of International Application No. PCT/EP2021/050366, filed internationally on Jan. 11, 2021, the disclosure of which is incorporated by reference in its entirety for all purposes.

US Referenced Citations (44)
Number Name Date Kind
3911108 Singh Oct 1975 A
4051235 Plymate Sep 1977 A
4644056 Kothe et al. Feb 1987 A
4784850 Abraham Nov 1988 A
5147548 Hies et al. Sep 1992 A
6096870 Mozaffar et al. Aug 2000 A
6162472 Griffin et al. Dec 2000 A
6444247 Gorewit Sep 2002 B1
8826810 Norelius Sep 2014 B1
9776138 Innings et al. Oct 2017 B2
20030059512 Kopf Mar 2003 A1
20040028667 Norman et al. Feb 2004 A1
20040219266 Milliken et al. Nov 2004 A1
20060102016 Ulrich et al. May 2006 A1
20060204632 Barrett-Reis et al. Sep 2006 A1
20060210668 Thorsoe Sep 2006 A1
20070166447 Ur-Rehman et al. Jul 2007 A1
20080050498 Sherwood Feb 2008 A1
20080075819 Hartmann et al. Mar 2008 A1
20090028990 Kwon et al. Jan 2009 A1
20100112152 Sinnema May 2010 A1
20100221359 Gohlke et al. Sep 2010 A1
20110206684 Medo Aug 2011 A1
20130059050 Fournell Mar 2013 A1
20140193555 Czank et al. Jul 2014 A1
20140271980 Eaker et al. Sep 2014 A1
20140272027 Elster et al. Sep 2014 A1
20140302219 Tikanmaki Oct 2014 A1
20150099036 Aichinger Apr 2015 A1
20150305383 Georgi et al. Oct 2015 A1
20160021904 Verdi Jan 2016 A1
20160362477 Sand et al. Dec 2016 A1
20170164630 Dimauro et al. Jun 2017 A1
20170172167 Silver et al. Jun 2017 A1
20170196234 Puigferrat et al. Jul 2017 A1
20170280737 Liao Oct 2017 A1
20180343880 Metzger Dec 2018 A1
20190223461 Ur-Rehman et al. Jul 2019 A1
20190263583 Downie et al. Aug 2019 A1
20190376942 Birlouez-Aragon Dec 2019 A1
20200196620 Arena et al. Jun 2020 A1
20200359642 Fournell Nov 2020 A1
20210239671 Suhr et al. Aug 2021 A1
20240009244 Yudina et al. Jan 2024 A1
Foreign Referenced Citations (126)
Number Date Country
105016 Mar 2003 BG
2360837 Aug 2000 CA
1037276 Nov 1989 CN
101014253 Aug 2007 CN
101605470 Dec 2009 CN
101731446 Jun 2010 CN
102630803 Aug 2012 CN
204466781 Jul 2015 CN
106417888 Feb 2017 CN
107576625 Jan 2018 CN
109122855 Jan 2019 CN
109452178 Mar 2019 CN
110214703 Sep 2019 CN
209628538 Nov 2019 CN
113457452 Jan 2021 CN
112642294 Apr 2021 CN
112913871 Jun 2021 CN
113287656 Aug 2021 CN
283937 Apr 1989 DE
4118168 Jan 1993 DE
9117058 Jun 1995 DE
19510969 Sep 1996 DE
19548221 May 1997 DE
102006053017 May 2008 DE
102013219932 Apr 2015 DE
102021105641 Sep 2022 DE
0173999 Mar 1986 EP
0316938 May 1989 EP
0338229 Oct 1989 EP
0391416 Oct 1990 EP
0398802 Nov 1990 EP
0410272 Jan 1991 EP
0363896 Aug 1994 EP
0638242 Feb 1995 EP
0741976 Nov 1996 EP
1055372 Nov 2000 EP
1637880 Mar 2006 EP
1982599 Oct 2008 EP
2280999 Feb 2011 EP
2572593 Mar 2013 EP
2762490 Aug 2014 EP
2833767 Feb 2015 EP
2675281 Apr 2015 EP
2896294 Jul 2015 EP
2926843 Oct 2015 EP
2992900 Mar 2016 EP
3056276 Aug 2016 EP
3225114 Oct 2017 EP
3281683 Feb 2018 EP
3298903 Mar 2018 EP
2914612 Nov 2018 EP
3476220 May 2019 EP
3496544 Jun 2019 EP
2334190 Sep 2020 EP
3175238 Aug 2021 EP
3855897 Aug 2021 EP
3949741 Feb 2022 EP
4063834 Sep 2022 EP
2273885 Jul 1994 GB
2525921 Nov 2015 GB
2544100 May 2017 GB
511562 Oct 2003 NZ
90318 Nov 1989 PT
WO-1989011226 Nov 1989 WO
WO-1995010192 Apr 1995 WO
WO-1996032021 Oct 1996 WO
WO-1999015024 Apr 1999 WO
WO-2000060949 Oct 2000 WO
WO-2001003515 Jan 2001 WO
WO-2003100377 Dec 2003 WO
WO-2006026879 Mar 2006 WO
WO-2006119560 Nov 2006 WO
WO-2007035870 Mar 2007 WO
WO-2008027572 Mar 2008 WO
WO-2008067486 Jun 2008 WO
WO-2008073888 Jun 2008 WO
WO-2008127104 Oct 2008 WO
WO-2008144922 Dec 2008 WO
WO-2008146276 Dec 2008 WO
WO-2009092629 Jul 2009 WO
WO-2009139624 Nov 2009 WO
WO-2010065652 Jun 2010 WO
WO-2010128051 Nov 2010 WO
WO-2012030764 Mar 2012 WO
WO-2012110705 Aug 2012 WO
WO-2013020081 Feb 2013 WO
WO-2013068653 May 2013 WO
WO-2013137714 Sep 2013 WO
WO-2013150070 Oct 2013 WO
WO-2014125382 Aug 2014 WO
WO-2014163486 Oct 2014 WO
WO-2015056166 Apr 2015 WO
WO-2015103561 Jul 2015 WO
WO-2015128512 Sep 2015 WO
WO-2015168418 Nov 2015 WO
WO-2016022152 Feb 2016 WO
WO-2016109659 Jul 2016 WO
WO-2016168167 Oct 2016 WO
WO-2016168698 Oct 2016 WO
WO-2017027081 Feb 2017 WO
WO-2017048881 Mar 2017 WO
WO-2017090049 Jun 2017 WO
WO-2017117409 Jul 2017 WO
WO-2017220697 Dec 2017 WO
WO-2018028764 Feb 2018 WO
WO-2018028765 Feb 2018 WO
WO-2018029222 Feb 2018 WO
WO-2018053535 Mar 2018 WO
WO-2018122695 Jul 2018 WO
WO-2018132676 Jul 2018 WO
WO-2018202636 Nov 2018 WO
WO-2019126308 Jun 2019 WO
WO-2019160402 Aug 2019 WO
WO-2019160416 Aug 2019 WO
WO-2020002422 Jan 2020 WO
WO-2020067883 Apr 2020 WO
WO-2020115196 Jun 2020 WO
WO-2020140185 Jul 2020 WO
WO-2020168439 Aug 2020 WO
WO-2020176607 Sep 2020 WO
WO-2020212954 Oct 2020 WO
WO-2022081623 Apr 2022 WO
WO-2022085007 Apr 2022 WO
WO-2022148549 Jul 2022 WO
WO-2022159989 Jul 2022 WO
WO-2022182837 Sep 2022 WO
Non-Patent Literature Citations (11)
Entry
Andreas et al., (2015). “Human Breast Milk: A review of its composition and bioactivity,” Early Human Development, 91(11):629-635, 19 pages.
Bertino et al., (2017). “New human milk fortifiers for the preterm infant,” Journal of Pediatric and Neonatal Individualized Medicine, 6(1):e060124, 7 pages.
Colaizy et al., (2016). “Impact of Optimized Breast Feeding on the Cost of Necrotizing Enterocolitis in Extremely Low Birthweight Infants,” J. Pediatr., 175:100-105.e2, 16 pages.
Embleton et al., (2013). “Effectiveness of Human Milk-Based Fortifiers for Preventing Necrotizing Enterocolitis in Preterm Infants: Case Not Proven,” Breastfeed. Med., 8(4):421.
International Search Report and Written Opinion received for International Patent Application No. PCT/EP2021/050366 mailed on May 7, 2021. 7 pages.
Lonnerdal et al., (2017). “Longitudinal evolution of true protein, amino acids and bioactive proteins in breast milk: a developmental perspective,” Journal of Nutritional Biochemistry, 41:1-11.
Martin et al., (2016). “Review of infant feeding: Key features of breast milk and infant formula,” Nutrients, 8(5):279, 11 pages.
Moro et al., (2015). “Human Milk in Feeding Premature Infants: Consensus Statement,” JPGN, 61(1):S16-S19.
Van't Land et al., (2010). “Chapter 2: Breast Milk: Components with Immune Modulating Potential and Their Possible Role in Immune Mediated Disease Resistance,” Dietary Components and Immune Function, 25-41.
Victora et al., (2016). “Breast feeding in the 21st century: Epidemiology, mechanisms, and lifelong effect,” Lancet, 387(10017):475-490, 16 pages.
Extended European Search Report and Opinion received for European Patent Application No. 23184820.1 mailed on Nov. 22, 2023, 9 pages.
Related Publications (1)
Number Date Country
20230220023 A1 Jul 2023 US
Continuations (1)
Number Date Country
Parent PCT/EP2021/050366 Jan 2021 WO
Child 18181939 US